Video yรผkleniyor...

Video Yรผklenemedi

Ana Sayfaya Dรถn

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

BiotechTV's profile picture

BiotechTV

11,738 subscribers

20,285 gรถrรผntรผleme โ€ข 6 ay รถnce โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gรถnderinin yorumlarฤฑ burada gรถrรผnecek

Benzer Videolar

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:
4:12

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:
4:45

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:

BiotechTV

10,996,973 gรถrรผntรผleme โ€ข 5 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:
6:11

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV

11,893 gรถrรผntรผleme โ€ข 5 ay รถnce

Company News: Nobel laureate @CarolynBertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates. Full video:
1:16

Company News: Nobel laureate @CarolynBertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates. Full video:

BiotechTV

14,355 gรถrรผntรผleme โ€ข 2 yฤฑl รถnce

A blizzard is not going to stop us. I made it to NYC meet with Fanatics Founder & CEO Michael Rubin.
0:26

A blizzard is not going to stop us. I made it to NYC meet with Fanatics Founder & CEO Michael Rubin.

Babz

897,677 gรถrรผntรผleme โ€ข 7 ay รถnce

.Savvy Wealth is modernizing the wealth management industry with its proprietary #technology. Co-Founder & CEO Ritik Malhotra tells us why he believes the space is ripe for #innovation on #NYSEFloorTalk.
6:27

.Savvy Wealth is modernizing the wealth management industry with its proprietary #technology. Co-Founder & CEO Ritik Malhotra tells us why he believes the space is ripe for #innovation on #NYSEFloorTalk.

NYSE ๐Ÿ›

16,189 gรถrรผntรผleme โ€ข 3 yฤฑl รถnce

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:
3:45

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!
1:37

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!

BiotechTV

12,358 gรถrรผntรผleme โ€ข 9 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:
4:58

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

BiotechTV

24,695 gรถrรผntรผleme โ€ข 8 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:
7:20

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

BiotechTV

37,174 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD. $OCUL Full video:
4:15

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD. $OCUL Full video:

BiotechTV

16,044 gรถrรผntรผleme โ€ข 7 ay รถnce

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:
3:11

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:

BiotechTV

15,086 gรถrรผntรผleme โ€ข 10 ay รถnce

๐„๐ฉ๐ข๐ ๐ž๐ง๐ž๐ญ๐ข๐œ๐ฌ: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.
3:01

๐„๐ฉ๐ข๐ ๐ž๐ง๐ž๐ญ๐ข๐œ๐ฌ: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

BiotechTV

85,263 gรถrรผntรผleme โ€ข 7 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:
7:29

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

BiotechTV

42,193 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!
0:48

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

BiotechTV

20,898 gรถrรผntรผleme โ€ข 3 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,956 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 gรถrรผntรผleme โ€ข 11 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:
2:56

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:

BiotechTV

13,213 gรถrรผntรผleme โ€ข 7 ay รถnce